Raju Prasad
Stock Analyst at William Blair
(0.10)
# 4,481
Out of 5,161 analysts
9
Total ratings
25%
Success rate
-34.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Raju Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DTIL Precision BioSciences | Downgrades: Market Perform | n/a | $5.67 | - | 1 | Jun 9, 2022 | |
| NTLA Intellia Therapeutics | Initiates: Outperform | n/a | $12.85 | - | 1 | Feb 18, 2022 | |
| ASMB Assembly Biosciences | Downgrades: Market Perform | n/a | $28.38 | - | 1 | Sep 2, 2021 | |
| TSHA Taysha Gene Therapies | Initiates: Outperform | $46 | $4.61 | +897.83% | 1 | Feb 24, 2021 | |
| CRSP CRISPR Therapeutics AG | Initiates: Market Perform | n/a | $48.87 | - | 1 | Mar 14, 2019 | |
| BOLD Boundless Bio | Downgrades: Market Perform | n/a | $1.13 | - | 2 | Nov 7, 2018 | |
| PTCT PTC Therapeutics | Upgrades: Outperform | n/a | $63.36 | - | 2 | Jun 18, 2018 |
Precision BioSciences
Jun 9, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $5.67
Upside: -
Intellia Therapeutics
Feb 18, 2022
Initiates: Outperform
Price Target: n/a
Current: $12.85
Upside: -
Assembly Biosciences
Sep 2, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $28.38
Upside: -
Taysha Gene Therapies
Feb 24, 2021
Initiates: Outperform
Price Target: $46
Current: $4.61
Upside: +897.83%
CRISPR Therapeutics AG
Mar 14, 2019
Initiates: Market Perform
Price Target: n/a
Current: $48.87
Upside: -
Boundless Bio
Nov 7, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $1.13
Upside: -
PTC Therapeutics
Jun 18, 2018
Upgrades: Outperform
Price Target: n/a
Current: $63.36
Upside: -